Researchers have developed an AI co-scientist workflow to discover new EGFR inhibitors, specifically targeting the C797S mutation that causes resistance to existing treatments. The process involves using ChEMBL and UniProt to identify biological targets and bioactivity data, then employing RDKit for molecular standardization and feature computation. A Random Forest model is trained on this data to predict inhibitor potency, with SHAP used for feature interpretation. Finally, the workflow moves into generative design by recombining molecular fragments with BRICS to create novel drug candidates, which are then scored and cross-checked against PubChem. AI
IMPACT This workflow demonstrates an integrated approach to drug discovery, potentially accelerating the identification of novel inhibitors for resistant mutations.
RANK_REASON The item describes the construction and methodology of a research workflow for drug discovery, not a new model release or frontier research. [lever_c_demoted from research: ic=1 ai=1.0]
AI-generated summary · Google Gemini · from 1 sources. How we write summaries →
